Hanx Biopharmaceuticals (Wuhan) Co., Ltd. released its prospectus for a Hong Kong Stock Exchange listing (HKG: 3378), offering 18,321,000 H‑shares at HK$28‑32 per share to raise up to HK$586 million (≈ US$75 M). The company is developing a pipeline of bispecific antibodies led by HX009, an anti‑PD‑1/SIRPα fusion protein in Phase 2 trials for oncology.
For Hanx: IPO proceeds will accelerate HX009 into Phase 3, fund manufacturing scale‑up for bispecific platforms, and advance a deep preclinical pipeline addressing oncology and autoimmune diseases.
For Investors: Offers exposure to China’s bispecific antibody boom with a platform validated by multiple clinical assets; HX009’s PD‑1/SIRPα mechanism is differentiated from standard PD‑1 monotherapy.
For Market: Adds a new competitor in the crowded PD‑1 space but with novel bispecific approach; potential for global out‑licensing if Phase 2 data readout is positive in 2026.
Forward‑Looking Statements This brief contains forward‑looking statements regarding the IPO timeline, HX009 clinical development, and market penetration. Actual results may differ due to market conditions, clinical risks, or competitive dynamics.-Fineline Info & Tech
